Floatz logo

Anti-Kirsten Rat Sarcoma Virus Glycine To Aspartic Acid Substitution At Codon 12 Peripheral Blood Lymphocytes

Gastric Cancer

National Cancer Institute (NCI)Cell therapyPhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

283 Active assets in the Gastric Cancer cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Irinotecan
Shenzhen Xinhe Biomedical
Phase 4BB
Cyclophosphamide
Vall d'Hebron Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Kirsten Rat Sarcoma Virus Glycine To Aspartic Acid Substitution At Codon 12 Peripheral Blood Lymphocytes is also rated in:

digestive system cancerDormant
CC
Indicative ·
45 / 100
View asset →
rectal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
colon carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →